Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | KST-6051 |
| Synonyms | |
| Therapy Description |
Limited information is currently available on KST-6051, a putative pan-KRAS inhibitor (Apr 2026). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| KST-6051 | KST6051|KST 6051 | KRAS Inhibitor 32 | Limited information is currently available on KST-6051, a putative pan-KRAS inhibitor (Apr 2026). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07458347 | Phase I | KST-6051 | A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation | Recruiting | USA | 0 |